AOD-9604 vs tesamorelin

AOD-9604 is a modified fragment of growth hormone investigated for metabolic effects; its major oral obesity study did not establish greater weight loss than placebo. Tesamorelin stimulates growth hormone release and reduced fat around abdominal organs in adults with HIV and lipodystrophy. Its approved use concerns that specific fat distribution, with little overall weight change. The two compounds have not been compared directly in the selected trials.

Research reviewed October 15, 2026. Educational information only.

A fragment of growth hormone and a signal that releases it

AOD-9604 is a sixteen-residue peptide made by adding tyrosine to the 177–191 fragment of human growth hormone. Its disulfide bond joins two cysteines, giving the molecule a looped region. That structure distinguishes it from unspecified growth-hormone fragments and from full-length growth hormone. FDA notes that clinical publications did not always establish the salt or free-base form used, which limits comparison between research preparations and products sold under the same name.

Tesamorelin is an analogue of the forty-four-residue growth hormone-releasing hormone. It stimulates the pituitary gland to release growth hormone, which subsequently increases insulin-like growth factor 1 (IGF-1), a growth-related protein. AOD-9604’s metabolic development sought effects separated from that growth-hormone/IGF-1 response; the human safety synthesis did not show an overall rise in IGF-1. Different biology makes their shared appearance in fat-loss discussions an inadequate basis for expecting the same effects.

The main differences

Animal fat-metabolism findings did not become established human weight loss

In genetically obese Zucker rats treated orally for nineteen days, AOD-9604 reduced weight gain: treated animals gained 15.8 ± 0.6 g compared with 35.6 ± 0.8 g in controls. Their fat tissue showed greater fat-breakdown activity. The animals still gained weight. The finding measures reduced weight gain in this rat model and supplies no human weight-loss estimate.

The clinical development tested a different question in adults with obesity. FDA’s account of the OPTIONS study describes 502 adults receiving oral AOD-9604 or placebo for twenty-four weeks alongside a diet and exercise program. Its primary comparison of weight loss after twelve weeks did not establish a benefit with AOD-9604, and the sponsor ended development for obesity. Detailed efficacy estimates were not available in the published medical literature reviewed by FDA. That unsuccessful comparison does not prove an effect of exactly zero; it leaves no established clinical weight-loss benefit and supplies no basis for substituting an injected product.

Tesamorelin reduced a particular abdominal fat compartment

Falutz and colleagues (2007) randomized 412 adults with HIV and abdominal fat accumulation to the original tesamorelin formulation or placebo for twenty-six weeks. CT scans measured fat inside the abdomen around organs, called visceral fat. Its measured area fell 15.2% with tesamorelin and rose 5.0% with placebo (P<0.001). These percentages describe changes in that fat compartment, rather than changes in total body weight.

Stanley and colleagues (2014) conducted a separate six-month trial that randomized fifty adults with HIV and abdominal fat accumulation, and forty-eight received study drug. Visceral-fat area was 42 cm² lower with tesamorelin relative to placebo (95% confidence interval 14–71 cm² lower). Liver lipid-to-water percentage decreased 2.0 percentage points with tesamorelin and increased 0.9 with placebo. These imaging findings support a specific body-composition effect; they do not establish prevention of heart attacks or later liver complications.

The current Egrifta WR label accordingly indicates reduction of excess abdominal fat in adults with HIV and lipodystrophy. It describes weight-neutral treatment and states that it is not indicated for weight-loss management. The newer WR and SV formulations have distinct product instructions and are not substitutable. Their labels describe how the approved products relate to the original research formulation; a marketed peptide with the same name does not automatically match those products.

Measured persistence depends on the peptide and product

The Egrifta WR label gives a mean tesamorelin elimination half-life of eleven minutes in healthy adults after subcutaneous administration of that formulation. A short peptide half-life can coexist with longer hormone and tissue responses, so it does not mean that the fat change lasts eleven minutes.

FDA’s AOD-9604 review did not identify a human pharmacokinetic study. Its approximately three-minute value comes from intravenous exposure in pigs; oral pig measurements were highly variable. Those animal values cannot be used to rank human formulations or supply a human injection schedule. No common human exposure dataset in these sources permits a direct half-life comparison.

The safety evidence differs in both depth and purpose

A sponsor-associated report combined safety observations from 893 participants across six AOD-9604 studies. It did not find an overall rise in IGF-1 or worsening glucose tolerance, and selected antibody tests were negative. The 893 figure includes participants in multiple studies and control groups; it is not 893 people given an injectable product. The detailed report includes possibly related severe chest tightness and serious diarrhea in different early studies. FDA separately identifies immune-reaction and impurity concerns and insufficient information to determine the safety of compounded AOD-9604.

Tesamorelin has a formal approved-product safety record. Its label warns about elevated IGF-1, fluid retention, glucose intolerance or diabetes, allergic reactions and injection-site reactions; active malignancy and pregnancy are contraindications. Long-term cardiovascular safety remains unestablished. Having an approved indication supplies a defined assessment of a particular product and population, without establishing safety for general fat loss or making it safer than AOD-9604 in an unperformed direct comparison.

The comparison turns on what changed and in whom

The strongest supported distinction is between an unsuccessful general-obesity development program and a demonstrated reduction in visceral abdominal fat in a defined HIV population. The studies did not randomize people between AOD-9604 and tesamorelin. Their different outcomes and populations prevent a numerical ranking for general weight loss, athletic body composition or long-term health.

The AOD-9604 profile explains the modified fragment and related research. The tesamorelin profile develops its compartment-specific fat findings and approved-product distinctions.

Frequently asked questions

Profiles and related reading

References

1. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee Meeting. AOD-9604-related bulk drug substances briefing document.

   FDA distinguishes the tyrosine-modified sixteen-residue AOD-9604 peptide from other growth-hormone fragments, reviews limited weight-loss evidence and finds no identified human pharmacokinetic study. Pig exposure measurements do not supply a human half-life.

2. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1–2):7–15. DOI: 10.4021/jem157w.

   Across six AOD9604 studies, the safety report did not find a rise in IGF-1 or worsening glucose tolerance overall. Its detailed results also include severe chest tightness and serious diarrhea considered possibly related to treatment.

3. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee Meeting. Official transcript, topic 2: AOD9604-related bulk drug substances.

   FDA describes the 502-person oral OPTIONS study: treatment lasted twenty-four weeks, while the primary weight-loss comparison at twelve weeks did not establish greater loss than placebo alongside diet and exercise support. The agency found the efficacy reporting insufficient to support an obesity-treatment claim.

4. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone research. 2000;53(6):274–278. doi:10.1159/000053183. PMID:11146367.

   In genetically obese rats, AOD9604 reduced weight gain and increased fat-breakdown activity in adipose tissue. These animal observations did not establish a human obesity effect.

5. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England journal of medicine. 2007;357(23):2359–2370. doi:10.1056/NEJMoa072375. PMID:18057338.

   Falutz and colleagues (2007) randomized 412 adults with HIV and abdominal fat accumulation to the original tesamorelin formulation or placebo for 26 weeks. Fat around the abdominal organs, measured by CT, decreased 15.2% with tesamorelin and increased 5.0% with placebo (P<0.001). IGF-1 rose 81.0% with tesamorelin and declined 5.0% with placebo.

6. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014 Jul 23-30;312(4):380–389. doi:10.1001/jama.2014.8334. PMID:25038357.

   Fifty adults with HIV and abdominal fat accumulation were randomized to tesamorelin or placebo. At six months, abdominal visceral-fat area was lower by 42 cm² relative to placebo (95% confidence interval 14–71 cm² lower); liver fat also declined.

7. Theratechnologies Inc. EGRIFTA WR (tesamorelin) for injection: U.S. prescribing information. Revised March 2025. DailyMed; accessed October 15, 2026.

   Egrifta WR is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. The label describes an eleven-minute mean peptide half-life for the WR formulation, weight-neutral use, diabetes and IGF-1 concerns, fluid retention and unestablished long-term cardiovascular safety.

8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Agency assessment; accessed October 15, 2026.

   FDA identifies possible immune reactions and peptide-impurity concerns for compounded AOD-9604. It lacks sufficient information to determine safety for the proposed uses.

9. U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs. Accessed October 15, 2026.

   FDA explains that compounded drugs are not FDA approved and are not reviewed before marketing for safety, effectiveness and quality in the same way as approved products.